Live Vaccine Against Measles, Mumps, and Rubella and the Risk of Hospital Admissions for Nontargeted Infections | Global Health | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.204.227.34. Please contact the publisher to request reinstatement.
1.
Aaby  P, Whittle  H, Benn  CS.  Vaccine programmes must consider their effect on general resistance.  BMJ. 2012;344:e3769.PubMedGoogle ScholarCrossref
2.
Aaby  P, Samb  B, Simondon  F, Seck  AM, Knudsen  K, Whittle  H.  Non-specific beneficial effect of measles immunisation: analysis of mortality studies from developing countries.  BMJ. 1995;311(7003):481-485.PubMedGoogle ScholarCrossref
3.
Aaby  P, Martins  CL, Garly  ML,  et al.  Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial.  BMJ. 2010;341:c6495.PubMedGoogle ScholarCrossref
4.
Aaby  P, Roth  A, Ravn  H,  et al.  Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period?  J Infect Dis. 2011;204(2):245-252.PubMedGoogle ScholarCrossref
5.
Biering-Sørensen  S, Aaby  P, Napirna  BM,  et al.  Small randomized trial among low-birth-weight children receiving bacillus Calmette-Guérin vaccination at first health center contact.  Pediatr Infect Dis J. 2012;31(3):306-308.PubMedGoogle ScholarCrossref
6.
Roth  AE, Benn  CS, Ravn  H,  et al.  Effect of revaccination with BCG in early childhood on mortality: randomised trial in Guinea-Bissau.  BMJ. 2010;340:c671.PubMedGoogle ScholarCrossref
7.
Shann  F.  The non-specific effects of vaccines.  Arch Dis Child. 2010;95(9):662-667.PubMedGoogle ScholarCrossref
8.
Benn  CS, Netea  MG, Selin  LK, Aaby  P.  A small jab—a big effect: nonspecific immunomodulation by vaccines.  Trends Immunol. 2013;34(9):431-439.PubMedGoogle ScholarCrossref
9.
Aaby  P, Benn  C, Nielsen  J, Lisse  IM, Rodrigues  A, Ravn  H.  Testing the hypothesis that diphtheria-tetanus-pertussis vaccine has negative non-specific and sex-differential effects on child survival in high-mortality countries.  BMJ Open. 2012;2(3):e000707.Google ScholarCrossref
10.
Aaby  P, Garly  ML, Nielsen  J,  et al.  Increased female-male mortality ratio associated with inactivated polio and diphtheria-tetanus-pertussis vaccines: observations from vaccination trials in Guinea-Bissau.  Pediatr Infect Dis J. 2007;26(3):247-252.PubMedGoogle ScholarCrossref
11.
Garly  ML, Jensen  H, Martins  CL,  et al.  Hepatitis B vaccination associated with higher female than male mortality in Guinea-Bissau: an observational study.  Pediatr Infect Dis J. 2004;23(12):1086-1092.PubMedGoogle Scholar
12.
Aaby  P, Ibrahim  SA, Libman  MD, Jensen  H.  The sequence of vaccinations and increased female mortality after high-titre measles vaccine: trials from rural Sudan and Kinshasa.  Vaccine. 2006;24(15):2764-2771.PubMedGoogle ScholarCrossref
13.
Kleinnijenhuis  J, Quintin  J, Preijers  F,  et al.  Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes.  Proc Natl Acad Sci U S A. 2012;109(43):17537-17542.PubMedGoogle ScholarCrossref
14.
Andersen  JS, Olivarius  NdeF, Krasnik  A.  The Danish National Health Service Register.  Scand J Public Health. 2011;39(7)(suppl):34-37.PubMedGoogle ScholarCrossref
15.
Pedersen  CB.  The Danish Civil Registration System.  Scand J Public Health. 2011;39(7)(suppl):22-25.PubMedGoogle ScholarCrossref
16.
Lynge  E, Sandegaard  JL, Rebolj  M.  The Danish National Patient Register.  Scand J Public Health. 2011;39(7)(suppl):30-33.PubMedGoogle ScholarCrossref
17.
Knudsen  LB, Olsen  J.  The Danish Medical Birth Registry.  Dan Med Bull. 1998;45(3):320-323.PubMedGoogle Scholar
18.
Baadsgaard  M, Quitzau  J.  Danish registers on personal income and transfer payments.  Scand J Public Health. 2011;39(7)(suppl):103-105.PubMedGoogle ScholarCrossref
19.
Jensen  VM, Rasmussen  AW.  Danish Education Registers.  Scand J Public Health. 2011;39(7)(suppl):91-94.PubMedGoogle ScholarCrossref
20.
Schoenfeld  D.  Partial residuals for the proportional hazards regression-model.  Biometrika. 1982;69(1):239-241.Google ScholarCrossref
21.
Cook  RJ, Lawless  JF.  General Intensity-Based Models. The Statistical Analysis of Recurrent Events. New York, NY: Springer; 2007:161-204.
22.
Andersen  PK, Keiding  N.  Multi-state models for event history analysis.  Stat Methods Med Res. 2002;11(2):91-115.PubMedGoogle ScholarCrossref
23.
Austin  PC.  Absolute risk reductions and numbers needed to treat can be obtained from adjusted survival models for time-to-event outcomes.  J Clin Epidemiol. 2010;63(1):46-55.PubMedGoogle ScholarCrossref
24.
Wójcik  OP, Simonsen  J, Mølbak  K, Valentiner-Branth  P.  Validation of the 5-year tetanus, diphtheria, pertussis and polio booster vaccination in the Danish childhood vaccination database.  Vaccine. 2013;31(6):955-959.PubMedGoogle ScholarCrossref
25.
Aaby  P, Bhuiya  A, Nahar  L, Knudsen  K, de Francisco  A, Strong  M.  The survival benefit of measles immunization may not be explained entirely by the prevention of measles disease: a community study from rural Bangladesh.  Int J Epidemiol. 2003;32(1):106-116.PubMedGoogle ScholarCrossref
26.
Kasongo Project Team.  Influence of measles vaccination on survival pattern of 7-35-month-old children in Kasongo, Zaire.  Lancet. 1981;317(8223):764-767.PubMedGoogle ScholarCrossref
27.
Aaby  P, Garly  ML, Balé  C,  et al.  Survival of previously measles-vaccinated and measles-unvaccinated children in an emergency situation: an unplanned study.  Pediatr Infect Dis J. 2003;22(9):798-805.PubMedGoogle ScholarCrossref
28.
Aaby  P, Martins  CL, Garly  ML, Rodrigues  A, Benn  CS, Whittle  H.  The optimal age of measles immunisation in low-income countries: a secondary analysis of the assumptions underlying the current policy.  BMJ Open. 2012;2(4):e000761.PubMedGoogle ScholarCrossref
29.
Martins  CL, Benn  CS, Andersen  A,  et al.  A randomized trial of a standard dose of Edmonston-Zagreb measles vaccine given at 4.5 months of age: effect on total hospital admissions [published online January 16, 2014].  J Infect Dis. doi:10.1093/infdis/jit804.Google Scholar
30.
Stowe  J, Andrews  N, Taylor  B, Miller  E.  No evidence of an increase of bacterial and viral infections following Measles, Mumps and Rubella vaccine.  Vaccine. 2009;27(9):1422-1425.PubMedGoogle ScholarCrossref
31.
Mullooly  JP, Schuler  R, Mesa  J, Drew  L, DeStefano  F; VSD Team.  Wheezing lower respiratory disease and vaccination of premature infants.  Vaccine. 2011;29(44):7611-7617.PubMedGoogle ScholarCrossref
32.
Hviid  A, Wohlfahrt  J, Stellfeld  M, Melbye  M.  Childhood vaccination and nontargeted infectious disease hospitalization.  JAMA. 2005;294(6):699-705.PubMedGoogle ScholarCrossref
33.
Aaby  P, Jensen  H, Samb  B,  et al.  Differences in female-male mortality after high-titre measles vaccine and association with subsequent vaccination with diphtheria-tetanus-pertussis and inactivated poliovirus: reanalysis of West African studies.  Lancet. 2003;361(9376):2183-2188.PubMedGoogle ScholarCrossref
34.
Farrington  CP, Firth  MJ, Moulton  LH, Ravn  H, Andersen  PK, Evans  S; Working Group on Non-specific Effects of Vaccines.  Epidemiological studies of the non-specific effects of vaccines: II—methodological issues in the design and analysis of cohort studies.  Trop Med Int Health. 2009;14(9):977-985.PubMedGoogle ScholarCrossref
35.
Carrillo-Santisteve  P, Lopalco  PL.  Measles still spreads in Europe: who is responsible for the failure to vaccinate?  Clin Microbiol Infect. 2012;18(suppl 5):50-56.PubMedGoogle ScholarCrossref
36.
Frølich  A, Schiøtz  ML, Strandberg-Larsen  M,  et al.  A retrospective analysis of health systems in Denmark and Kaiser Permanente.  BMC Health Serv Res. 2008;8:252.PubMedGoogle ScholarCrossref
37.
Davis  K.  The Danish health system through an American lens.  Health Policy. 2002;59(2):119-132.PubMedGoogle ScholarCrossref
38.
Kamper-Jørgensen  M, Wohlfahrt  J, Simonsen  J, Thrane  N, Benn  CS.  Temporal trend in paediatric infections in Denmark.  Arch Dis Child. 2006;91(5):401-404.PubMedGoogle ScholarCrossref
Original Investigation
February 26, 2014

Live Vaccine Against Measles, Mumps, and Rubella and the Risk of Hospital Admissions for Nontargeted Infections

Author Affiliations
  • 1Research Center for Vitamins and Vaccines (CVIVA), Bandim Health Project, Statens Serum Institut, Copenhagen, Denmark
  • 2Institute of Clinical Research, University of Southern Denmark, and Odense University Hospital, Odense, Denmark
  • 3Bandim Health Project, INDEPTH Network, Bissau, Guinea-Bissau
  • 4Child and Adolescent Clinic, Rigshospitalet, Copenhagen, Denmark
  • 5Department of Infectious Disease Epidemiology, Statens Serum Institut, Copenhagen, Denmark
JAMA. 2014;311(8):826-835. doi:10.1001/jama.2014.470
Abstract

Importance  In low-income countries, live measles vaccine reduces mortality from causes other than measles infection. Such nonspecific effects of vaccines might also be important for the health of children in high-income settings.

Objective  To examine whether the live vaccine against measles, mumps, and rubella (MMR) is associated with lower rates of hospital admissions for infections among children in Denmark.

Design, Setting, and Participants  Population-based cohort study of Danish children born 1997-2006 and followed up from ages 11 months to 2 years (last follow-up, August 31, 2008). Nationwide Danish registers provided data on vaccinations and hospital admissions. The recommended vaccination schedule was inactivated vaccine against diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae type b (DTaP-IPV-Hib) administered at ages 3, 5, and 12 months and MMR at age 15 months.

Main Outcomes and Measures  Incidence rate ratios (IRRs) of hospital admissions for any infection, comparing receipt of MMR vs DTaP-IPV-Hib as the most recent vaccine. Risks, risk difference, and number needed to vaccinate were calculated for receiving MMR on time.

Results  The study included 495 987 children contributing with 56 889 hospital admissions for any type of infection during 509 427 person-years (rate, 11.2 per 100 person-years). For the 456 043 children who followed the recommended schedule and received MMR after the third dose of DTaP-IPV-Hib, MMR (rate, 8.9 per 100 person-years) vs the third dose of DTaP-IPV-Hib (rate, 12.4 per 100 person-years) as the most recent vaccine was associated with an adjusted IRR of 0.86 (95% CI, 0.84-0.88) for any admission for infection. There were 19 219 children immunized out of sequence. The adjusted IRR was 0.87 (95% CI, 0.80-0.95) for those receiving MMR (rate, 9.9 per 100 person-years) after the second dose of DTaP-IPV-Hib (rate, 15.1 per 100 person-years). However, in the 1981 children who subsequently received the third dose of DTaP-IPV-Hib (rate, 12.8 per 100 person-years) after MMR, the IRR for hospital admissions for infection was significantly greater (adjusted IRR, 1.62 [95% CI, 1.28-2.05]). The risk of admission for an infection between ages 16 months and 24 months was 4.6% (95% CI, 4.5%-4.7%) for receiving MMR on time and 5.1% (95% CI, 5.0%-5.2%) for not receiving MMR on time. The risk difference was 0.5 percentage point (95% CI, 0.4-0.6), and the number needed to vaccinate with MMR before age 16 months to prevent 1 admission for any infection was 201 (95% CI, 159-272).

Conclusions and Relevance  In a cohort of Danish children, receipt of live MMR vs inactivated DTaP-IPV-Hib as the most recent vaccine was associated with a lower rate of hospital admissions for any infections. These findings require replication in other high-income populations.

×